✦ LIBER ✦

Progress in the treatment of acute myeloid leukaemia in adults

✍ Scribed by Adrian Newland

Publisher: Carden Jennings Publishing
Year: 2002
Tongue: English
Weight: 729 KB
Volume: 76
Category: Article
ISSN: 0925-5710
DOI: 10.1007/bf03165254

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progress in the treatment of acute myelo

Progress in the treatment of acute myeloid leukemia

✍ Farhad Ravandi; Alan K. Burnett; Edward D. Agura; Hagop M. Kantarjian 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

## Abstract Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous molecular abnormalities that may be responsible for leukemogenesis. Over the same period, large trials have established standard regi

Clofarabine in the treatment of poor ris

Clofarabine in the treatment of poor risk acute myeloid leukaemia

✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ

The oxydase reaction in acute myeloid le

The oxydase reaction in acute myeloid leukæmia

✍ Piney, A. 📂 Article 📅 1925 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 163 KB

Oral idarubicin in the treatment of acut

Oral idarubicin in the treatment of acute myelogenous leukaemia and the blast phase of chronic myeloid leukaemia

✍ S. T. A. Malik; J. Tucker; A. Z. S. Rohatiner; W. Brace; T. A. Lister 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/ day). No complete remissions or return to chronic phase CML were observed. A fall in the per

The therapy of relapsed acute leukaemia

The therapy of relapsed acute leukaemia in adults

✍ Mark R Litzow 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 438 KB

Although the cure of acute leukaemia has improved significantly, many patients will still relapse and die. The unraveling of the molecular pathogenesis of acute leukaemia has lead to the identification of new prognostic factors and improved the detection of minimal residual disease. The treatment of

Relevance of clinical trials in acute my

Relevance of clinical trials in acute myeloid leukaemia

✍ Apostolia M. Tsimberidou; Elihu Estey 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

## Abstract Patients with newly diagnosed acute myeloid leukaemia (AML) are increasingly being enrolled in clinical trials sponsored by pharmaceutical companies or the National Cancer Institute. These trials routinely exclude patients who are less likely to respond (LLTR), e.g. those with Zubrod pe